sulfamethoxypyridazine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
Sulfamethoxypyridazine: A sulfanilamide antibacterial agent.
sulfamethoxypyridazine : A sulfonamide consisting of pyridazine having a methoxy substituent at the 6-position and a 4-aminobenzenesulfonamido group at the 3-position.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Melo, ACC | 1 |
| Santana, JMSVP | 1 |
| Nunes, KJRC | 1 |
| Rodrigues, BL | 1 |
| Castilho, N | 1 |
| Gabriel, P | 1 |
| Moraes, AH | 1 |
| Marques, MA | 1 |
| de Oliveira, GAP | 1 |
| de Souza, ÍP | 1 |
| Terenzi, H | 1 |
| Pereira-Maia, EC | 1 |
1 other study available for sulfamethoxypyridazine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
New Heteroleptic Ruthenium(II) Complexes with Sulfamethoxypyridazine and Diimines as Potential Antitumor Agents.
Topics: Antineoplastic Agents; Circular Dichroism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-A | 2019 |